Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.APP Pharmaceuticals, a manufacturer of multi-source and branded injectable pharmaceutical products, has launched rocuronium bromide injection, the generic equivalent of Organon's Zemuron.
Subscribe to our email newsletter
APP’s rocuronium is AP-rated and preservative-free, and is marketed in two dosage forms, 50mg/5ml and 100mg/10ml. It is a nondepolarizing neuromuscular blocking agent that unlike other NMBA’s provides immediate muscular relaxation, the company said.
Used predominately in hospitals and clinics in general anesthesia, rocuronium is an intravenous neuromuscular blocking agent (NMBA) that is administered during surgery to facilitate safe and rapid endotracheal intubation and provide total skeletal muscle relaxation.
Thomas Silberg, president and CEO of APP Pharmaceuticals, said: “In addition to safety measures such as barcoding and latex-free stoppers, APP has incorporated a peel off syringe label on all of its rocuronium vials.
“Adding this feature to the vials enables healthcare facilities to comply with National Patient Safety Goal 3D, which requires labeling on all medications, syringes for perioperative and other procedural settings.”